Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 3,64 € (+405,56%). La mediana è 3,64 € (+405,56%).
| Acquista |
6 |
| Mantieni |
1 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
PDS Biotechnology completes private placement of $11.3 million led by Soon-Shiong
PDS Biotechnology has completed a first tranche of a private placement with gross proceeds of about $11.3 million, led by Nant Capital. The company issued common stock, prepaid warrants and accompanying warrants at prices around $0.282 and intends to use the net proceeds to repay liabilities and as working capital for clinical development. The transaction includes a contingent milestone closing under which Nant and AB Group would invest an additional $10 million and $1 million, respectively, upon filing an FDA protocol for a Phase 3 trial of PDS0301. PDS granted NantWorks a one-year right to negotiate an exclusive license to PDS0101, and Dr. Patrick Soon-Shiong and James Banaag will join the board of directors. » Altro su de.investing.com
PDS Biotechnology secures up to 22.55 million USD in private placement led by Nant Capital
PDS Biotechnology has secured up to 22.55 million USD in a private placement led by Nant Capital. The initial closing is expected to raise about 11.55 million USD through the sale of common shares or prepaid warrants at 0.2825 USD per unit; a further milestone-dependent closing of 11 million USD will be triggered upon filing an FDA protocol for a Phase 3 study of PDS0301. Nant Capital will have the right to appoint two board members, including Dr. Patrick Soon-Shiong, if it reaches an economic stake of at least 15%. The proceeds will be used to repay indebtedness, for working capital, to further develop clinical programs, and for research and administration; NantWorks also received a one-year exclusive negotiation right for a license to PDS0101. » Altro su de.investing.com
PDS Biotechnology names interim CFO after resignation of Lars Boesgaard
Lars Boesgaard submitted his resignation as CFO effective September 12, 2026; his departure is not related to any disagreements over the company’s business operations. The board appointed Janetta Trochimiuk as acting head of accounting and CEO Dr. Frank Bedu-Addo as acting chief financial officer, both positions effective September 12, 2026. Trochimiuk will retain her current base salary and remain eligible under the existing equity incentive plan; no new equity awards were granted. At the annual general meeting, shareholders approved increasing the number of authorized common shares from 150 million to 300 million. » Altro su de.investing.com
PDS Biotechnology increases authorized common shares to 300 million and elects two directors
Shareholders of PDS Biotechnology approved an amendment to increase the authorized common shares from 150 million to 300 million; the vote was 19,904,111 in favor and 11,545,436 against. At the annual meeting, where roughly 56.6% of outstanding shares were represented, Kamil Ali-Jackson and Ilian Iliev were elected as Class B directors. Shareholders also ratified KPMG US LLP as the independent registered public accounting firm for fiscal 2026 and approved a non-binding, advisory say-on-pay vote. » Altro su de.investing.com
PDS Biotechnology surpasses Q1 2026 EPS forecast after significant cost cuts
PDS Biotechnology reported Q1 2026 EPS of -$0.13, beating the analyst expectation of -$0.15. The company cut R&D expenses by 39.7% and reduced the net loss to $7.3 million, while cash and cash equivalents stood at $21.7 million. Strategic adjustments to the VERSATILE‑003 study are intended to accelerate the approval process; despite improvements, losses are still expected in coming quarters. The stock rose 6.36% in premarket trading on positive investor reaction. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | 0 | - |
| Utile netto | -6,73 Mln | 12,36% |
| EBITDA | -5,21 Mln | 22,22% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 44,42 Mln € |
Numero di azioni | 55,82 Mln |
Massimo/minimo a 52 settimane | 1,63 € - 0,18 € |
| Dividendi | No |
Beta | 1,45 |
Rapporto P/E | -1,56 |
Rapporto PEG | -0,04 |
Rapporto P/B | 0,00 |
Rapporto P/S | 0,00 |
Profilo aziendale
PDS Biotechnology Corporation, una società biofarmaceutica in fase di sviluppo clinico, si concentra sullo sviluppo di immunoterapie multifunzionali contro il cancro. Il suo principale candidato prodotto è PDS0101 (HPV16), che si trova in fase II di sperimentazione clinica e offre un trattamento di prima linea per il carcinoma della testa e del collo recidivante/metastatico, per le neoplasie associate al papillomavirus umano e per il cancro della cervice uterina. La società sta inoltre sviluppando vari candidati prodotto, che si trovano in fase di sperimentazione preclinica, tra cui PDS0102, la proteina TARP (T-cell receptor gamma alternate reading frame protein) per il trattamento del cancro alla prostata e al seno; PDS0103 (MUC-1) per i tumori dell'ovaio, del colon-retto, del polmone e del seno; e PDS0104, che comprende la Tyrosinase-related protein 2 per il trattamento del melanoma. Inoltre, sviluppa PDS0201 per il trattamento della tubercolosi; PDS0202, un candidato vaccino antinfluenzale; e PDS0203, un vaccino per la prevenzione della COVID-19. La società ha accordi di licenza e di collaborazione con i National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services e MSD International GmbH. PDS Biotechnology Corporation è stata fondata nel 2005 ed ha sede a Florham Park, New Jersey.
| Nome | PDS BIOTECHNOLOGY CORP. |
| CEO | Frank K. Bedu-Addo |
| Sede centrale | Princeton,
nj Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 30/09/2015 |
| Dipendenti | 21 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | PDSB |
Frankfurt | EU6.F |
Düsseldorf | EU6.DU |
München | EU6.MU |